	Page One OUTCOME OF LIVING DONOR LIVER TRANSPLANTATION (LDLT) : GRAFT SURVIVAL IS POOR ESPECIALLY IN HCV RECIPIENTS
	A RANDOMISED DOUBLE-BLIND PHASE II STUDY OF LAMIVUDINE (LAM) COMPARED TO LAMIVUDINE PLUS ADEFOVIR DIPIVOXIL (ADV) FOR TREATMENT NAìVE PATIENTS WITH CHRONIC HEPATITIS B (CHB) : WEEK 52 ANALYSIS
	SIMVASTATIN AMMELIORATES THE INCREASED HEPATIC VASCULAR TONE IN PATIENTS WITH CIRRHOSIS
	Page two
	TENOFOVIR EFFECTIVELY INHIBITS VIRAL REPLICATION IN DIFFERENT PATIENT GROUPS WITH LAMIVUDINE RESISTANT HBV INFECTION
	LIVER FIBROSIS REGRESSES BETTER WITH PEGINTERFERON ALPHA AND URSODEOXYCHOLIC ACID TREATMENT THAN SPONTANEOUS RECOVERY
	EFFECT OF HBV AND HCV COINFECTION ON ANTI-VIRAL T CELL RESPONSES
	A RANDOMIZED CONTROLLED TRIAL OF PEGYLATED-INTERFERON ALPHA-2B + RIBAVIRIN VS INTERFERON ALPHA-2B + RIBAVIRIN IN HIV CO-INFECTED PATIENTS Page three COMBINATION OF PEGYLATED INTERFERON AND LAMIVUDINE IS SUPERIOR TO LAMIVUDINE MONOTHERAPY IN THE TREATMENT OF CHRONIC HEPATITIS B - A RANDOMIZED TRIAL
	PREDICTORS OF VIROLOGIC RESPONSE IN COMBINATION THERAPY WITH INTERFERON (IFN) ALFA 2B PLUS RIBAVIRIN OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION (LT)
	PREDCTIVE FACTORS OF HCC RECURRENCE AFTER LIVER TRANSPLANTATION (OLT) : AN INTERIM ANALYSIS
	Factors Associated With recurrence After Liver transplantation For Hepatocellular Carcinoma
	A STUDY OF THE PRESENCE OF HCV RNA IN SEMEN OF PATIENTS WITH CHRONIC HCV INFECTION Page Four
	EFFICACY OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN FOR 24 WEEKS IN GENOTYPE 1 PATIENTS WITH CHRONIC HEPATITIS C FOLLOWED BY MONO OR COMBINATION THERAPY FOR 22 WEEKS: PRELIMINARY ANALYSIS OF AN OPEN, MULTICENTER, RANDOMIZED TRIAL
	Entecavir for HBV in Lamivudine Failures
	EFFICIENCY OF DNA VACCINE IN ASSOCIATION WITH LAMIVUDINE FOR CHRONIC HEPATITIS B THERAPY
	THE EFFECT OF PEGINTERFERON ALFA-2A (40 KD) ON LIVER HISTOLOGY IN CHRONIC HEPATITIS C: A META-ANALYSIS OF INDIVIDUAL PATIENTS DATA
	Clevudine, New Drug for HBV
	PHARMACOKINETICS OF PEGINTERFERON ALFA-2A (40KD, PEGASYS) COMPARED TO PEGINTERFERON ALFA-2B (12KD, PEGINTRON) IN NAIVE PATIENTS WITH CHRONIC HEPATITIS C (CHC)
	Study Suggests More Than 48 Weeks Therapy for Patients with high baseline viral loads, HCV genotype 1, and cirrhosis may be necessary
	72 weeks HCV Therapy (PegIFN/RBV): is it effective?